secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001517022-24-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q1 net loss narrows to $18M; Vafseo FDA approved, launch set for Jan 2025
--------------------------------------------------------------------------------

- Total revenues $32.6M (Q1 2024) vs $40.0M (Q1 2023); Auryxia net product revenues $31.0M vs $34.7M.
- Net loss of $18.0M improved from $26.9M loss in prior year; R&D spend reduced to $9.7M from $19.7M.
- Vafseo (vadadustat) FDA approved Mar 27 for dialysis anemia; launch activities underway, availability Jan 2025.
- Drew $7.5M second tranche from BlackRock debt facility; $10M remaining borrowing capacity through Dec 31, 2024.
- Amended Vifor license agreement: repayment of working capital fund via tiered royalties on Vafseo sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000050/0001517022-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000050/akba-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer